Hypertension, Tachycardia, and Reversible Cardiomyopathy Temporally Associated with Milnacipran Use

Overview

Journal Tex Heart Inst J

Specialty Cardiology & Vascular Diseases

Date 2011 Dec 27

PMID 22199446

Citations 5

Authors

Mervyn B Forman

Paul G Sutej

Edwin K Jackson

Affiliations

Soon will be listed here.

Abstract

Elevated catecholamine levels are a well-recognized cause of various types of cardiomyopathy. Causes of catecholamine elevation include tumors, toxins, drugs, emotional stress, and sepsis. Milnacipran is a dual and equipotent inhibitor of norepinephrine and serotonin uptake. It is frequently prescribed as therapy for fibromyalgia, and the drug has a good safety profile. Herein, we report the case of a 42-year-old woman with undefined connective-tissue disease and fibromyalgia who developed a severe and reversible cardiomyopathy while taking recommended doses of milnacipran. The cardiomyopathy was associated with a hyperadrenergic state manifested by tachycardia, hypertension, and elevated plasma catecholamine levels. The discontinuation of milnacipran and the initiation of anti-failure therapy resulted in complete resolution of the cardiomyopathy in 6 months. To our knowledge, this is the first report of milnacipran as a possible cause of catecholamine-induced cardiomyopathy.

Citing Articles

Takotsubo Cardiomyopathy and Autoimmune Disorders: A Systematic Scoping Review of Published Cases.

Kouhanjani M, Hosseini S, Mousavi S, Noroozi Z, Sadeghi P, Jokar-Derisi A Int J Clin Pract. 2024; 2024:7259200.

PMID: 38414580 PMC: 10898954. DOI: 10.1155/2024/7259200.

Pharmacological Triggers of Takotsubo Cardiomyopathy: An Updated Review of Evidence and Recommendations.

Arunkumar S, Jegaverrapandi K Curr Cardiol Rev. 2024; 20(2):50-60.

PMID: 38367261 PMC: 11107468. DOI: 10.2174/011573403X273613240125072754.

Update of Takotsubo cardiomyopathy: Present experience and outlook for the future.

Bairashevskaia A, Belogubova S, Kondratiuk M, Rudnova D, Sologova S, Tereshkina O Int J Cardiol Heart Vasc. 2022; 39:100990.

PMID: 35281752 PMC: 8913320. DOI: 10.1016/j.ijcha.2022.100990.

Antidepressant Drugs Effects on Blood Pressure.

Calvi A, Fischetti I, Verzicco I, Belvederi Murri M, Zanetidou S, Volpi R Front Cardiovasc Med. 2021; 8:704281.

PMID: 34414219 PMC: 8370473. DOI: 10.3389/fcvm.2021.704281.

Takotsubo Cardiomyopathy: Medical and Psychiatric Aspects. Role of Psychotropic Medications in the Treatment of Adults with "Broken Heart" Syndrome.

Zvonarev V Cureus. 2019; 11(7):e5177.

PMID: 31423403 PMC: 6695293. DOI: 10.7759/cureus.5177.

References

Selke K, Dhar G, Cohn J . Takotsubo cardiomyopathy associated with titration of duloxetine. Tex Heart Inst J. 2011; 38(5):573-6. PMC: 3231522. View

Periclou A, Palmer R, Zheng H, Lindamood 3rd C . Effects of milnacipran on cardiac repolarization in healthy participants. J Clin Pharmacol. 2010; 50(4):422-33. DOI: 10.1177/0091270009346059. View

Doherty N, Siegel R . Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J. 1985; 110(6):1257-65. DOI: 10.1016/0002-8703(85)90023-7. View

Friedrich M, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper L . Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009; 53(17):1475-87. PMC: 2743893. DOI: 10.1016/j.jacc.2009.02.007. View

Ratliff N, Estes M, Myles J, SHIREY E, McMahon J . Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med. 1987; 316(4):191-3. DOI: 10.1056/NEJM198701223160405. View

Mease P, Clauw D, Gendreau R, Rao S, Kranzler J, Chen W . The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009; 36(2):398-409. DOI: 10.3899/jrheum.080734. View

Costedoat-Chalumeau N, Hulot J, Amoura Z, Delcourt A, Maisonobe T, Dorent R . Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology. 2006; 107(2):73-80. DOI: 10.1159/000094079. View

Mosca M, Tani C, Bombardieri S . Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol. 2007; 21(6):1011-23. DOI: 10.1016/j.berh.2007.09.004. View

Vaz C, Couto M, Medeiros D, Miranda L, Costa J, Nero P . Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009; 28(8):915-21. DOI: 10.1007/s10067-009-1175-2. View

10.

Christoph M, Ebner B, Stolte D, Ibrahim K, Kolschmann S, Strasser R . Broken heart syndrome: Tako Tsubo cardiomyopathy associated with an overdose of the serotonin-norepinephrine reuptake inhibitor Venlafaxine. Eur Neuropsychopharmacol. 2010; 20(8):594-7. DOI: 10.1016/j.euroneuro.2010.03.009. View

11.

Sutherland J, Al Chekakie M, Moran J . Catecholamine-induced cardiomyopathy rapidly reversed with beta-blocker therapy. Congest Heart Fail. 2009; 15(4):193-5. DOI: 10.1111/j.1751-7133.2009.00079.x. View

12.

Montgomery S . Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr. 2008; 13(7 Suppl 11):27-33. DOI: 10.1017/s1092852900028297. View

13.

Clauw D, Mease P, Palmer R, Gendreau R, Wang Y . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008; 30(11):1988-2004. DOI: 10.1016/j.clinthera.2008.11.009. View

14.

Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M . Cardiac involvement in systemic lupus erythematosus. Lupus. 2005; 14(9):683-6. DOI: 10.1191/0961203305lu2200oa. View

15.

Budhwani N, Bonaparte K, Cuyjet A, Saric M . Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose. Rev Cardiovasc Med. 2004; 5(2):130-3. View

16.

Kassim T, Clarke D, Mai V, Clyde P, Shakir K . Catecholamine-induced cardiomyopathy. Endocr Pract. 2009; 14(9):1137-49. DOI: 10.4158/EP.14.9.1137. View

17.

Lundberg I . Cardiac involvement in autoimmune myositis and mixed connective tissue disease. Lupus. 2005; 14(9):708-12. DOI: 10.1191/0961203305lu2205oa. View

18.

Caron J, Libersa C, Hazard J, Lacroix D, Facq E, Guedon-Moreau L . Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol. 1993; 3(4):493-500. DOI: 10.1016/0924-977x(93)90274-p. View

19.

de Toledo Ferraz Alves T, Guerra De Andrade A . Hypertension induced by regular doses of milnacipran: a case report. Pharmacopsychiatry. 2007; 40(1):41-2. DOI: 10.1055/s-2006-958723. View

20.

Yoshida K, Higuchi H, Takahashi H, Shimizu T . Elevation of blood pressure induced by high-dose milnacipran. Hum Psychopharmacol. 2002; 17(8):431. DOI: 10.1002/hup.432. View